Compare CVKD & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVKD | NAII |
|---|---|---|
| Founded | 2022 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 21.2M |
| IPO Year | 2023 | 1987 |
| Metric | CVKD | NAII |
|---|---|---|
| Price | $9.94 | $3.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | 28.8K | ★ 29.0K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $134,440,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 19.00 |
| 52 Week Low | $8.12 | $2.57 |
| 52 Week High | $22.90 | $4.40 |
| Indicator | CVKD | NAII |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 46.13 |
| Support Level | $8.12 | $3.42 |
| Resistance Level | $11.58 | $3.68 |
| Average True Range (ATR) | 0.88 | 0.20 |
| MACD | 0.09 | -0.04 |
| Stochastic Oscillator | 46.06 | 19.67 |
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.